Skip to Content
Merck

Decoding myofibroblast origins in human kidney fibrosis.

Nature (2020-11-12)
Christoph Kuppe, Mahmoud M Ibrahim, Jennifer Kranz, Xiaoting Zhang, Susanne Ziegler, Javier Perales-Patón, Jitske Jansen, Katharina C Reimer, James R Smith, Ross Dobie, John R Wilson-Kanamori, Maurice Halder, Yaoxian Xu, Nazanin Kabgani, Nadine Kaesler, Martin Klaus, Lukas Gernhold, Victor G Puelles, Tobias B Huber, Peter Boor, Sylvia Menzel, Remco M Hoogenboezem, Eric M J Bindels, Joachim Steffens, Jürgen Floege, Rebekka K Schneider, Julio Saez-Rodriguez, Neil C Henderson, Rafael Kramann
ABSTRACT

Kidney fibrosis is the hallmark of chronic kidney disease progression; however, at present no antifibrotic therapies exist1-3. The origin, functional heterogeneity and regulation of scar-forming cells that occur during human kidney fibrosis remain poorly understood1,2,4. Here, using single-cell RNA sequencing, we profiled the transcriptomes of cells from the proximal and non-proximal tubules of healthy and fibrotic human kidneys to map the entire human kidney. This analysis enabled us to map all matrix-producing cells at high resolution, and to identify distinct subpopulations of pericytes and fibroblasts as the main cellular sources of scar-forming myofibroblasts during human kidney fibrosis. We used genetic fate-tracing, time-course single-cell RNA sequencing and ATAC-seq (assay for transposase-accessible chromatin using sequencing) experiments in mice, and spatial transcriptomics in human kidney fibrosis, to shed light on the cellular origins and differentiation of human kidney myofibroblasts and their precursors at high resolution. Finally, we used this strategy to detect potential therapeutic targets, and identified NKD2 as a myofibroblast-specific target in human kidney fibrosis.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-DACH1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution